1 etation of both planar and SPECT V/Q scans are variable
and data are lacking regarding which criteria are commonly used i
2 Because data are lacking for many species, most studies that model fu
3 e isoflurane binding sites in NaV, but experimental
binding data are lacking.
4 would require disclosure and written informed consent,
but data are lacking on the views of potential participants.
5 rus (HIV) + liver transplantation (LT) are encouraging,
but data are lacking regarding long-term outcomes and comparisons
6 viable treatment for select patients with HIV and ESRD,
but data are lacking regarding long-term outcomes and comparisons
7 s a risk factor for developing rhinitis/rhinosinusitis,
but data are lacking.
8 s has been studied in murine and ex vivo human studies,
but data are lacking from patients with invasive fungal infection
9 er glycemic control than sensor-augmented pump therapy,
but data are lacking on the efficacy, safety, and feasibility of
10 rt dietary LComega3PUFA protection against DR, but
clinical data are lacking.
11 Prospective
clinical data are lacking.
12 recent years, yet long-term, modality-specific
comparative data are lacking.
13 However,
conclusive data are lacking as to whether moderate pain should be treate
14 However,
conclusive data are lacking for the efficacy and safety of colchicine fo
15 Contemporary data are lacking on the prognostic importance of heart failur
16 Current data are lacking for incidence, correlates, and prognosis ass
17 se and affect the health of the public; however,
definitive data are lacking.
18 cies' potential range shifts, especially when more
detailed data are lacking on dispersal dynamics, demographic processes
19 (NETs) are thought to be rising, but updated
epidemiologic data are lacking.
20 ife-threatening emergency of which reliable
epidemiological data are lacking.
21 rophylaxis are rare complications for which
epidemiological data are lacking.
22 ollutants, including perchloroethylene (PERC),
experimental data are lacking, resulting in default assumptions being used
23 Genomic data are lacking for many allergen sources.
24 However,
data are lacking on long-term PPI use and cognitive function.
25 However,
data are lacking on the cardiovascular safety of degludec.
26 However,
data are lacking regarding optimal timing and dosing of ASA.
27 shown improved short-term outcomes; however, long-term
HRQL data are lacking.
28 ive phosphorylation and improve metabolic health, but
human data are lacking.
29 n the early origins of obesity, but intergenerational
human data are lacking.We prospectively investigated refined-grain
30 quencing, but direct comparisons between models and "
omics"
data are lacking.
31 Long-term
outcome data are lacking, and the effectiveness of therapy in this pa
32 reported hot flush severity, but underpinning
physiological data are lacking.
33 Although firm
prevalence data are lacking, there is a strong impression that food alle
34 ive chemoradiation over surgery alone, although
prospective data are lacking.
35 n-small cell lung cancer (NSCLC), but long-term
prospective data are lacking.
36 However, longitudinal
QOL data are lacking on whether weight loss improves QOL.
37 ility to generate reactive oxygen species, but
quantitative data are lacking.
38 h acute type A aortic dissection, but reliable
quantitative data are lacking.
39 Reliable data are lacking on pregnancy outcomes during Ebola virus dis
40 Recent antimicrobial
resistance data are lacking from inpatient oncology settings to guide in
41 However,
similar data are lacking for the cellular response, which in gnathost
42 llites can capture snapshots of this construction, but
such data are lacking in temporal resolution and spatial scope.
43 aria over time from large areas of the continent where
such data are lacking need to be prioritized.
44 possibility of distinct binding sites, although
supporting data are lacking.
45 Survival data are lacking for kidney transplant recipients with rare n
46 Long-term
survival data are lacking, and prognostic factors are not well defined
47 Long-term
survival data are lacking, and prognostic factors are not well defined
48 Therefore,
data are lacking on the short- and long-term clinical outcome
49 s of mammalian steady-state metabolomic and
transcriptional data are lacking.
50 phosphatase expression as a biomarker, though phase 3
trial data are lacking.